STOK
Stoke Therapeutics, Inc.
+1.14 (+4.08%)29.05USD311K成交股數1.9B市值–本益比(近四季)68.0股價營收比-32.5%營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 9.3M-94% | 6.2M-72% | 10.6M+117% | 13.8M+186% | 159M+3661% | 22.6M+584% | 4.9M-297% | 4.8M-6% | 4.2M | 3.3M | −2.5M | 5.2M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 49.5M | 39.7M | 37.7M | 25.9M | 32.7M | 23.4M | 22.2M | 21.1M | 22.4M | 20.3M | 20.6M | 19.6M |
| 銷售管理費用 | 25.3M | 20.0M | 16.0M | 15.3M | 14.7M | 12.8M | 12.7M | 13.0M | 10.2M | 10.3M | 10.2M | 10.2M |
| 營業利益 | −65.4M-159% | −53.4M+291% | −43.1M+44% | −27.3M-7% | 111M-492% | −13.7M-50% | −30.0M-10% | −29.3M+19% | −28.4M | −27.2M | −33.3M | −24.7M |
| 營業利益率 | -701.7% | -857.6% | -405.3% | -197.6% | 70.2% | -60.4% | -613.1% | -607.4% | -673.0% | -823.3% | 1,340.7% | -479.2% |
| 稅後淨利 | −61.6M-155% | −50.0M+377% | −38.3M+45% | −23.5M-9% | 113M-528% | −10.5M-57% | −26.4M-14% | −25.7M+14% | −26.4M | −24.5M | −30.7M | −22.5M |
| 淨利率 | -660.8% | -802.7% | -360.7% | -170.0% | 71.2% | -46.4% | -540.0% | -531.9% | -625.6% | -741.9% | 1,235.6% | -437.6% |
| 稀釋 EPS | -0.93-149% | -0.79+427% | -0.65+38% | -0.40-13% | 1.90-433% | -0.15-73% | -0.47-32% | -0.46-13% | -0.57 | -0.55 | -0.69 | -0.53 |
| 稀釋股數 | 66.0M | 63.1M | 58.6M | 58.4M | 59.4M | 54.0M | 56.3M | 55.8M | 46.2M | 44.3M | 44.2M | 42.5M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 110M | 156M | 83.4M | 101M | 275M | 128M | 150M | 193M | 179M | 190M | 192M | 190M |
| 應收帳款 | 7.2M | 4.5M | 9.2M | – | – | 1.7M | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 394M | 443M | 360M | 385M | 407M | 272M | 293M | 308M | 205M | 240M | 257M | 282M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 48.4M | 48.4M | 52.2M | 49.6M | 56.8M | 42.5M | 61.2M | 65.0M | 64.8M | 66.9M | 66.7M | 68.0M |
| 股東權益 | 346M | 395M | 308M | 335M | 350M | 229M | 232M | 243M | 140M | 173M | 190M | 214M |
| 負債比 | 12.3% | 10.9% | 14.5% | 12.9% | 14.0% | 15.7% | 20.9% | 21.1% | 31.6% | 27.9% | 26.0% | 24.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −60.6M | – | – | 132M-637% | – | – | – | −24.6M | – | – | −21.4M |
| 資本支出 | – | 353K | – | – | 152K | – | – | – | 12K | – | – | 165K |
| 自由現金流 | – | −60.9M | – | – | 132M-636% | – | – | – | −24.6M | – | – | −21.5M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -978.2% | – | – | 83.0% | – | – | – | -583.0% | – | – | -417.7% |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 184M | +404.5% | −6.9M | -3.7% | -0.12 | 44.9M |
| FY2024 | 36.6M | +316.3% | −89.0M | -243.4% | -1.65 | −87.1M |
| FY2023 | 8.8M | -29.2% | −105M | -1,192.5% | -2.38 | −82.7M |
| FY2022 | 12.4M | – | −101M | -814.7% | -2.60 | −35.8M |
| FY2021 | – | – | −85.8M | –% | -2.34 | −68.1M |
| FY2020 | – | – | −52.2M | –% | -1.56 | −43.3M |
| FY2019 | – | – | −32.3M | –% | -1.80 | −32.7M |
| FY2018 | – | – | −12.5M | –% | -17.65 | −11.9M |